Le Lézard
Classified in: Health, Business
Subject: LIC

Goldfinch Bio Announces Collaborations with Icahn School of Medicine at Mount Sinai and Vanderbilt University Medical Center to Augment World's Largest Genomic Registry of Patients with Kidney Disease

CAMBRIDGE, Mass., Oct. 17, 2017 /PRNewswire/ -- Goldfinch Bio, a company singularly focused on discovering and developing precision therapies to treat patients with kidney disease, today announced collaborations with the Icahn School of Medicine at Mount Sinai and Vanderbilt University Medical Center to generate genomic data on over 1,500 patients with proteinuric kidney disease. The collaborations will integrate genomic analysis and de-identified clinical data from Mount Sinai's BioMe BioBank and Vanderbilt's BioVU BioBank to expand Goldfinch's Patient Registry, generating an unparalleled collection of insights from patients with kidney disease.

Goldfinch Bio is leading a new age of therapeutic discovery and development in the kidney space, and is building the world's largest genomic registry of patients with kidney disease to inform new disease targets, pathways, and biomarkers for the discovery and development of novel therapies. The patient registry is a key component of the company's integrated product engine, which will drive breakthroughs in genetics and biology to bring precision medicines to patients with kidney disease.

In October 2017, Goldfinch announced the Company's foundational patient registry collaboration with The Nephrotic Syndrome Study Network (NEPTUNE), a network of academic centers focused on clinical and translational research on kidney diseases presenting as Nephrotic Syndrome. The collaborations with Mount Sinai and Vanderbilt University Medical Center build upon this foundation, creating a comprehensive, federated database that integrates patient clinical data with molecular characterization at the DNA, RNA, and protein level. 

"We are thrilled to work with the Icahn School of Medicine at Mount Sinai and Vanderbilt University Medical Center to advance our understanding of the molecular pathways of kidney disease and bring precision medicines to patients," stated Abbie Celniker, Ph.D., interim chief executive officer of Goldfinch.

About Goldfinch Bio
Goldfinch Bio is a biotechnology company that is singularly focused on discovering and developing precision therapies for patients with kidney disease. Just as the goldfinch has long been a symbol of healing and renewal and was a prominent figure of the Renaissance, Goldfinch Bio is leading a new age of therapeutic discovery to transform the treatment paradigm for people with kidney disease. Goldfinch was launched in 2016 by Third Rock Ventures, and is headquartered in Cambridge, Mass. For more information, please visit www.goldfinchbio.com.

Goldfinch Bio Contact
Jennifer Williams
Cook Williams Communications, Inc.


SOURCE Goldfinch Bio

These press releases may also interest you

at 14:01
After just a year in business, Dr. Keith Ablow, the renowned psychiatrist, New York Times bestselling self-help author and television personality has doubled the size of Blue Water Wellness his Newburyport, MA mind-body medspa. Dr. Ablow was the...

at 14:00
It's no secret that pets make our lives happier and healthier. And for many families, the benefits pets provide will soon come at a time and place they may never have expected: during their child's hospital stay. Today, Mars Petcare and Monroe Carell...

at 14:00
The "US Product Portfolio for Interventional Cardiology 2018 - MedFolio" report has been added to ResearchAndMarkets.com's offering. There are many different types of complementary devices used during interventional cardiology procedures. These...

at 14:00
FLUSHING, N.Y., July 18, 2018 /PRNewswire-PRWeb/ -- Calcium & Bone Health Institute (CBHI), partnering with Pronuvia, Inc., has initiated to introduce the revolutionary Sigma Anti-Bonding Calcium (SAC) to medical industry. Recently, the inventor of...

at 14:00
Alcami Corporation, a leading provider of fully-integrated custom end-to-end solutions for the pharmaceutical and biotechnology industries, today announced a renewed partnership with the Wisconsin Department of Natural Resources (DNR) to revitalize...

at 13:58
Care Bridge International, a data analytics firm, today announced a new white paper that uses a massive claims database to estimate the true exposure of future medical treatment and costs in Medicare Set Asides for Workers Compensation claims.  The...

News published on 17 october 2017 at 07:30 and distributed by: